


FIG. 1A




FIG. 1B




FIG. 1C



1.E+07
1.E+06
1.E+05
1.E+04
1.E+03
1.E+02
1.E+01
1.E+00
1.E-01
1.E-02
1.E-03
Infectivity (pfu/mL)
y=2E+06e^-1.7228x
R^2=0.9865
~8 kGy
~0 pfu
0
2
4
6
8
10
12
14
Irradiation Dose (kGy)

FIG.2A



4096
2048
1024
512
256
128
64
32
NT50 titer
0 KGy
7.2 KGy
14.4 KGy
AD169
naive
Revertant vaccine

FIG.2B



1.E+08
1.E+07
1.E+06
1.E+05
1.E+04
1.E+03
1.E+02
1.E+01
1.E+00
Infectivity (pfu/mL)
0% BPL
0.01% BPL
0.1% BPL
~8 hr
~2.5 pfu/mL
0 2 4 6 8 10 12 14 16 18 20 22 24
Elapsed Time (hours)

FIG.2C



8192
4096
2048
1024
512
256
128
64
32
16
NT50 titer
1 hr
2 hr
4 hr
6 hr
22 hr
No BPL
AD169
naive
time treated with BPL @ 0.1%

FIG.2D



0 μM
0.05 μM
0.1 μM
0.5 μM
2 μM
TCID50/ml, Log 10
0
1
2
3
4
5
6
7
ddIE1/2
ddUL51
ddUL52
ddUL79
ddUL84
ddUL87
ddIE1/2-UL51
Mutant viruses

FIG.3




FIG.4A




FIG.4B




FIG.4C




FIG.4D




FIG.5A




FIG.5B




FIG.5C




FIG.5D




FIG.5E




FIG.6A




FIG.6B




FIG.6C



100µg/dose in HNS
10µg/dose with IMX
10µg/dose in HNS
gB/MF59
10µg/dose with AAHS
NT50 titers
100,000
10,000
1,000
100
10
0
10
20
30
40
50
60
70
80
Study week

FIG. 7



ELISPOT (sfc/10^6 PBMC)
1000
900
800
700
600
500
400
300
200
100
0
mock
IE1
IE2
pp65
gB
pp150(1/2)

FIG.8A



ELISPOT (sfc/10^6 PBMC)
1000
900
800
700
600
500
400
300
200
100
0
mock
IE1
IE2
pp65
gB
pp150(1/2)

FIG.8B



ELISPOT (sfc/10^6 PBMC)
1000
900
800
700
600
500
400
300
200
100
0
mock
IE1
IE2
pp65
gB
pp150(1/2)

FIG.8C



ELISPOT (sfc/10^6 PBMC)
1000
900
800
700
600
500
400
300
200
100
0
mock
IE1
IE2
pp65
gB
pp150(1/2)

FIG.8D



100μg Vaccine
10μg with IMX
Naive
CD8+IFNg+ / 10^6 PBMC
10000
1000
100
10
1
Mock
pp65
1E1
1E2
CMV
SEB
Stimulation

FIG.9A



100μg Vaccine
10μg with IMX
Naive
CD4+IFNg+ / 10^6 PBMC
10000
1000
100
10
1
Mock
pp65
1E1
1E2
CMV
SEB
Stimulation

FIG.9B



p=0.128
p=0.1331
NT50 titer
32768
16384
8192
4096
2048
1024
512
256
128
64
32
16
2200
1300
5800
HNS
AAHS
MAPA

FIG. 10




FIG.11A




FIG.11B




FIG.12A




FIG.12B




FIG. 13A




FIG. 13B




FIG. 14A




FIG. 14B



EC50 (μg/mL)
2.5
2
1.5
1
0.5
0
HBSS (−70°C)
9% Sucrose
150 mM NaCl
9% Sucrose+150 mM NaCl
5% Sucrose+75 mM NaCl
3% Sucrose+50mM Proline
2.5% Sorbitol+75 mM NaCl
1.25% Glycerol+75 mM NaCl

FIG. 15




FIG. 16A




FIG. 16B